Provided by Tiger Trade Technology Pte. Ltd.

Macrogenics

4.14
+0.01000.24%
Post-market: 4.12-0.0200-0.48%19:47 EDT
Volume:873.94K
Turnover:3.61M
Market Cap:263.49M
PE:-18.07
High:4.17
Open:4.12
Low:4.09
Close:4.13
52wk High:5.08
52wk Low:1.29
Shares:63.65M
Float Shares:56.42M
Volume Ratio:2.39
T/O Rate:1.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2291
EPS(LYR):-1.1815
ROE:-225.85%
ROA:-8.05%
PB:6.15
PE(LYR):-3.50

Loading ...

MacroGenics Q1 revenue rises, beats estimates on client production and cancer drug royalties

Reuters
·
May 14

MacroGenics Q1 FY26 net loss narrows to $36.8 million; revenue rises to $20.8 million

Reuters
·
May 14

BRIEF-MacroGenics Q1 Net Income USD -36.8 Million

Reuters
·
May 14

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

GlobeNewswire
·
May 14

Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks

Simply Wall St.
·
May 13

MacroGenics sells GMP manufacturing operations to Bora for $122.5 million upfront payment

Reuters
·
May 12

MacroGenics Inc - to Sell Gmp Manufacturing Operations to Bora

THOMSON REUTERS
·
May 12

MacroGenics to Sell Gmp Manufacturing Operations to Bora Pharmaceuticals

THOMSON REUTERS
·
May 12

MacroGenics Inc - to Enter Supply Arrangement With Bora for Process Development and Drug Substance Production for Its Internal Pipeline Needs

THOMSON REUTERS
·
May 12

MacroGenics Inc: to Receive $122.5 Mln Upfront Payment From Bora Upon Closing

THOMSON REUTERS
·
May 12

MacroGenics trading halted, news pending

TIPRANKS
·
May 12

NASDAQ TRADE HALT HALT NEWS PENDING AT 04:25 PM

Reuters
·
May 12

MacroGenics sells capped Zynyz royalty interest to Sagard for $60 million

Reuters
·
May 04

BRIEF-Macrogenics And Sagard Healthcare Partners Enter Into Expanded Zynyz® Royalty Purchase Agreement

Reuters
·
May 04

MacroGenics Inc - All Royalty Rights Revert to MacroGenics After Sagard Receives 1.7X or 2.0X Investment by September 30, 2032

THOMSON REUTERS
·
May 04

MacroGenics Inc - Receives $60 Mln Upfront, Eligible for up to $20 Mln 2026 Milestone

THOMSON REUTERS
·
May 04

MacroGenics and Sagard Healthcare Partners Enter Into Expanded Zynyz® Royalty Purchase Agreement

THOMSON REUTERS
·
May 04

Macrogenics Is Maintained at Overweight by Barclays

Dow Jones
·
Apr 20

Macrogenics Raised to Buy From Neutral by B. Riley Securities

Dow Jones
·
Apr 11

B. Riley Upgrades MacroGenics to Buy From Neutral, Triples Price Target to $9 From $3

MT Newswires Live
·
Apr 10